Mabqi is proud to announce its participation in the 67th American Society of Hematology (ASH) Annual Meeting, taking place in Orlando, Florida, from December 6–9, 2025.
As part of the scientific program, Johanna Marines, PharmD, Head of the Preclinical Team at Mabqi, will present the latest preclinical in vivo results of MQI-181, our novel pH-sensitive ADC for hematology-oncology during the poster session.
MQI-181 is a tumor-specific immunotherapy designed for lymphoma and other blood cancers, specifically targets the TME with the potential to evolve into a next-generation ADC. In-vivo data are available, and the program is currently open for partnering opportunities.
The ASH Annual Meeting is the world’s leading hematology conference, bringing together thousands of clinicians, researchers, and industry leaders to share breakthroughs, discuss emerging therapies, and explore innovations transforming patient care.
By presenting our pioneering work on MQI-181, Mabqi aims to foster scientific exchange, advance treatment possibilities for blood cancers, and explore strategic collaborations.
Orlando, here we come!
